Eurofins Viracor BioPharma, a division of Eurofin Scientific, a leading bio-analytical tester and service provider, is grounded with its footprint and best-in-class laboratory services from Luxembourg. The company serves its remarkable services for consumer products, pharmaceutical, environmental and food sectors. Eurofins, along with its above 65,000 workforce and 900+ laboratory operations in 62 countries, offers a comprehensive above 200,000 analytical solutions/techniques to strengthen the sectors’ business game.
Eurofin’s Viracor BioPharma Services has declared the expansion of its powerful service portfolio. The portfolio expansion will be integrated with improved bioanalytical testing potential to make the expansion more qualitative and convincing. The new expanding services are in sync with Good Clinical Practices (GCP) and Good Laboratory Practices (GLP). This synchronisation will help the company to contribute precisely in biopharmaceutical development programs with peak scientific explanation in the responsible drug development operations.
This brilliant move of Eurofin came out confidently as the company is enjoying the progress in unification and a new site to mark and register more of Eurofins Pharma Bioanalytics Services' excellence from St. Charles, Missouri. Further, this success lands in Eurofins Viracor BioPharma’s intentional Lenexa, Kansas facility. The company initiative to bring both of the laboratories' strengths under one roof has become possible due to the bioanalytical organisation’s ‘YES’.
The double power laboratory is thoughtfully engineered to support the crucial clinical trials and offer comprehensive data integrity, well-mannered workflows and a sincere quality sample management. With this extension to the services, the company has now turned into a full-fledged bioanalytical service provider. The service pumps up the method establishment, green signal and proven/qualified sample analysis with clear regulatory guidance.
The company proved its dedication and commitment to valuable investment in spectacular laboratory infrastructure, modern quality systems and scientific leadership. This is a push for the biopharmaceutical innovators who find it difficult to tackle the advanced drug development needs. These extended facilities are the place for new and fundamental therapies to come into the healthcare light and continue the growth of modern drug development.
The rising demand for advanced therapies is definitely rising, but the company spotted the actual and obvious need for advanced space for the advanced therapies. Eurofins' support will bring new collaborations and business to the healthcare sector, which will eventually fuel the company’s business. The healthcare suite is, anyway, awaiting powerful innovations and support for the same.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
